U023 Knowing Lichenoid Dermatoses: Common Pathways and Treatments
DESCRIPTION
Lichenoid dermatoses include a broad spectrum of diseases with overlapping clinical and histological features. However, it remains unclear whether distinct lichenoid dermatoses such as lichen planus and lichen planopilaris share a common immunopathogenesis. This session will provide a cutting-edge overview on the immunopathogenesis of lichenoid dermatoses with particular emphasis on lichen planus, lichen planopilaris and lichen planus pigmentosus. The session will highlight recent advances in our understanding of these related lichenoid as systemic diseases and discuss their associated comorbidities. Finally, this session will discuss current and emerging therapeutic options for the practicing dermatologist.
LEARNING OBJECTIVES
Summarize the current evidence for distinct and shared pathogenesis mechanisms of lichenoid dermatoses.
Recognize that lichen planus and lichen planopilaris are systemic diseases with associated comorbidities.
Discuss new upcoming treatments for lichen planus, lichen planopilaris and lichen planus pigmentosus.
SCHEDULE
4:30 PM
Immunopathogenesis of lichenoid dermatoses: continuation on a spectrum?
Matthew Vesely, MD, PhD, FAAD
4:45 PM
Lichen planus and lichen planopilaris as systemic diseases
Jeffrey Marcus Cohen, MD, FAAD
5:00 PM
Lichen planopilaris and Lichen planus pigmentosus: current and emerging therapies
Crystal Aguh, MD, FAAD
5:15 PM
Q&A session
DIRECTOR
Matthew Vesely, MD, PhD, FAAD
SPEAKERS
Crystal Aguh, MD, FAAD
Jeffrey Marcus Cohen, MD, FAAD
HANDOUTS
DISCLOSURES
Crystal Aguh, MD, FAAD
CP Skin Health – Advisory Board(Honoraria); Eli Lilly and Company – Consultant(Fees); Johnson & Johnson – Other(Residency/Fellowship Program Funding); Pfizer Inc. – Consultant(Fees); Procter & Gamble Company – Consultant (1099 relationship)(Fees); UpToDate, Inc – Other(Fees); Veradermics – Advisory Board(Fees);
Jeffrey Marcus Cohen, MD, FAAD
Advarra – Data Safety Monitoring Board(Fees); GlaxoSmithKline Immunology – Consultant (1099 relationship)(Honoraria); Imagene Bio – Consultant (1099 relationship)(Honoraria); Johnson & Johnson – Advisory Board(Honoraria); JORA Immunology – Founder(Stock); Logical Images, Inc – Consultant(Honoraria); Novartis – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria);
Matthew Vesely, MD, PhD, FAAD
Aclaris Therapeutics Inc. – Investigator(Grants/Research Funding); Almirall – Consultant (1099 relationship)(Fees); First Tracks Biotherapeutics – Advisory Board(Fees); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Regeneron – Employee(Salary);